Ribociclib Shown to Penetrate the Blood-Brain Barrier in Glioblastoma
A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors.
Head and Neck Cancer
HEAD AND NECK CANCER ADVISOR
FEATURED CONTENT
-
-
Comparison Study Shows Predictive Value for CSCC of the Head and Neck of BWH vs AJCC 8
A team of researchers sought to determine if BWH Tumor Classification System classified tumors more accurately than AJCC 8, and their sensitivity and specificity for predicting poor outcomes. -
Does Radioactive Iodine Treatment for Hyperthyroidism Confer A Higher Cancer Risk?
Over the past decade, researchers have found inconsistent evidence about whether radioactive iodine treatment for hyperthyroidism can cause cancer in the long term. -
Tapping Into the Therapeutic Expertise of High-Volume Cancer Centers
Researchers examine how patient outcomes could be affected if patients were to receive systemic drug treatment at dedicated cancer centers versus at community health systems. -
New Trial Attempts to Make Genetic Counseling and Testing More Accessible
The researchers wrote that “genetic counseling must be further explored to find an optimal balance of clinical quality with increased access and financial sustainability.”
HEAD AND NECK CANCER NEWS
Immunological Profiling of High-Grade Gliomas Reveals Subtypes That Influence Survival
Following NCCN Surveillance Guidelines in Oropharyngeal Carcinoma Did Not Yield a Survival Benefit: Study
Minority, Low-Income Individuals Less Likely to Receive Oral Cancer Screening
Rozlytrek, a Tumor Agnostic Therapy, Receives FDA Approval
Treatment Reduction in Intermediate-Risk Neuroblastoma Deemed Successful
Want to read more?
Please login or register first to view this content.
Next post in Head and Neck Cancer
